Veru Stock
Veru Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Mitchell S. Steiner
- Employees
- 20
- Market cap
- $39 M
- IPO
- 11/02/1999
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This…
Veru stock: price history
1D
-5.7%
1W
-6.5%
1M
-0.9%
6M
-5.7%
YTD
+7.5%
1Y
-44.8%
2Y
-74.8%
5Y
-97.3%
10Y
-77.2%
Next earnings date
Next earnings date
26/11/2026 (in 40 days)
Volatility around earnings
~37% stronger price swings than usual
Ask the agents about Veru
Analyst assessment of Veru
PRICE TARGET LOW
US$3.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 04/06/2026
Veru stock metrics
P/E
-3.83
P/B
1.87
EV/EBITDA
-0.67
RETURN ON EQUITY
-24.6%
NET MARGIN
0.0%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.9%
FLOAT SHARES
14,987,282
AVG. DAILY VOLUME (30D)
244,831
Insider transactions (SEC)
BARNETTE K GARY
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Veru stock
What does Veru do?
Veru Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Mitchell S. Steiner, the company employs around 20 people.
The IPO was on 11/02/1999; the stock trades on NASDAQ under the ticker VERU.
What do analysts say about Veru stock?
7 analysts rate the stock, the consensus is Buy (as of 04/06/2026).
The average price target is US$4.00, ranging from US$3.00 to US$5.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Veru report next?
The next earnings date is 26/11/2026.
Around past earnings, price swings were roughly 37% stronger than usual.
Does Veru pay a dividend?
Yes. The last dividend was US$0.07 per share, ex-date 28/04/2014, paid on 07/05/2014.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Veru?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Veru stock analyzed?
Clicking "Analyze stock" lets five strategies assess Veru against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.